Dermatology

A New Drug Application has been submitted to the FDA for potential approval of roflumilast foam 0.3% for the treatment of seborrheic dermatitis in adults and adolescents.

A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.

An interview with Victoria Barrio, MD, and Fabiana Castro Porto Silva Lopes, MD, about the Society for Pediatric Dermatology and its efforts to address diversity in the dermatology field.

A 16-year-old boy with developmental delay and intellectual disability developed dramatic chronic wrinkling of his scalp over a year ago. The lesions were persistent but not symptomatic. What's the diagnosis?

Arcutis Biotherapeutics, Inc has submitted a supplemental New Drug Application for roflumilast cream (ZORYVE) to the US Food and Drug Administration for treatment of plaque psoriasis in children aged 2 to 11 years.

A recent article highlighted multiple therapies for treating atopic dermatitis, including many which do not require a prescription.

A recent article highlighted multiple forms of treatment for atopic dermatitis, detailing their benefits and adverse events.

Adults with atopic dermatitis saw improved symptoms when taking dupilumab compared to placebo, regardless of the age when they first presented with the condition.

Pediatric care requires understanding, not only of the disease impact, but also its presentation and management in children.

Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

Dermavant Sciences recently announced positive results for VTAMA (tapinarof cream, 1%) for treatment of atopic dermatitis in children aged as young as 2 years.

You are asked to evaluate an African American boy aged 4 years with a birthmark on his back and right arm. He is healthy with normal growth and development. What's the diagnosis?

You are asked to evaluate a healthy 1.5-day-old girl who has a congenital red patch with coarse telangiectasias and a surrounding ring of pallor on the right shoulder. What's your diagnosis?

The parents of a 3-month-old girl seek medical advice regarding recent seizures and a facial birthmark. What’s the diagnosis?

New research suggests the sleep quality of caregivers and patients with atopic dermatitis (inadequately-controlled with topical therapies) may improve with dupilumab treatment.

New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in children and adolescents.

This case study analyzes variants of majocchi granuloma and potential treatment.

At the 2022 AAP National Conference & Exhibition, a presenter delves into diagnosis and management of common and uncommon skin rashes in newborns.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

A previously healthy 11-year-old boy presents with purpuric macules and papules symmetrically distributed on his buttocks and upper and lower extremities. What’s the diagnosis?

A 4-week-old boy presents with creamy white patches on his lips, right and left buccal mucosa, palate, and tongue.

Investigators have found that there are limited options for treating pediatric psoriasis.

Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.

Arcutis Biotherapeutics’ roflumilast cream will provide relief to patients aged 12 years or older diagnosed with plaque psoriasis.

A healthy 14-year old boy was evaluated for an intensely pruritic shin rash that developed 2 weeks prior and had been treated with oral antibiotics for 10 days.

Opzelura (ruxolitinib) cream is the first and only FDA-approved treatment for adult and pediatric patients 12 years of age or older with vitiligo.

A better understanding of this atopic diathesis and the atopic march often seen in pediatric patients is necessary to optimally treat and manage the patient population, ideally in a multidisciplinary setting.

At an SPD 2022 47th Annual Meeting poster session, researchers look at gender and age differences in pediatric patients with melanoma.

At the SPD 2022 47th Annual Meeting, a poster session looks at the updated guidelines for rosacea, and whether they are inclusive of children.